Effect of CYP2D6*4, CYP2D6*10 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma

Larisa K. Moshetova; Maria M. Soshina; Ksenia I. Turkina; Elena A. Grishina; Zhannet A. Sozaeva; Anastasia A. Kachanova; Kristina A. Akmalova; Dmitriy V. Ivashchenko; Mikhail S. Zastrozhin; Vladimir P. Fisenko; Dmitry A. Sychev

doi:10.1515/dmpt-2022-0117

Artikel

Effect of CYP2D64, CYP2D610 polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma

Larisa K. Moshetova , Maria M. Soshina , Ksenia I. Turkina , Elena A. Grishina , Zhannet A. Sozaeva , Anastasia A. Kachanova , Kristina A. Akmalova , Dmitriy V. Ivashchenko , Mikhail S. Zastrozhin , Vladimir P. Fisenko und Dmitry A. Sychev

Veröffentlicht/Copyright: 24. August 2022

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen

Aus der Zeitschrift Drug Metabolism and Personalized Therapy Band 38 Heft 2

Abstract

Objectives

Timolol maleate is used for the treatment of glaucoma and metabolized by cytochrome CYP2D6 in the liver. The aim of this study was the evaluation of the influence of CYP2D6*4 and CYP2D6*10 gene polymorphisms on the safety of medications containing 0.5% of timolol maleate as glaucoma treatment in patients with primary open-angle glaucoma (POAG).

Methods

105 patients with POAG were prescribed glaucoma medications, containing 0.5% timolol maleate. The safety of glaucoma treatment was determined by electrocardiography (ECG) (to assess heart rate (HR) and PQ interval) and blood pressure (BP) measurements. The real-time polymerase chain reaction method was used for the detection of single nucleotide polymorphisms (SNP).

Results

The risk of adverse drug reactions was higher in patients with the CYP2D6*4 GA genotype compared with GG: mean HR change at 1 month (2.88 ± 4.68 and 6.44 ± 5.57, p<0.001) and 6 months (5.14 ± 8.93 and 7.88 ± 5.65, p<0.001), mean PQ interval change at 1 (0.01 ± 0.031 and 0.02 ± 0.022, p=0.003) and 6 months (0.01 ± 0.032 and 0.02 ± 0.024, p=0.003). The risk of adverse drug reactions was higher in patients with the CYP2D6*10 CT genotype compared with CC: mean HR change at 1 month (2.94 ± 4.65 and 6.34 ± 5.66, p<0.001) and 6 months (5.20 ± 8.90 and 7.78 ± 5.75, p<0.001), mean PQ interval change at 1 (0.01 ± 0.032 and 0.02 ± 0.021, p=0.014) and 6 months (0.01 ± 0.033 and 0.02 ± 0.022, p=0.014).

Conclusions

CYP2D6*4 and CYP2D6*10 gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timolol maleate in patients with POAG.

Keywords: CYP2D6; glaucoma; ophthalmic timolol; pharmacogenetics; polymorphism

Corresponding author: Maria M. Soshina, Researcher, Department of Ophthalmology, Russian Medical Academy of Continuing Professional Education, 2/1-1 Barrikadnaya str., 125993 Moscow, Russian Federation, Phone: +7 (925) 888-03-97, E-mail: greenmaha@yandex.ru

Funding source: The Ministry of Health of the Russian Federation for the Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia for 2022–2024

Award Identifier / Grant number: (No. 121110800062–6)

Acknowledgments

Special thanks to Anastasia Samoilova, the student of New York University, for help in translating the article.

Research funding: This study was carried out within the framework of the state task of the Ministry of Health of the Russian Federation for the Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia for 2022–2024 (No. 121110800062–6).
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Competing interest: Authors state no conflict of interest.
Conflict of interest statement: The authors declare no conflicts of interest regarding this article.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The protocol of this study was reviewed and approved by the local Ethics Committee of the Russian Medical Academy of Postgraduate Education (Act No 12, date of act 08.11.2016).

References

1. Udovichenko, EV, Zhirov, AL, Sorokin, EL. Unreasonable diagnosis of glaucoma and one-stage prescription of hypotensive therapy. Reflection 2019;9:40–3. https://doi.org/10.25276/2686-6986-2019-2-40-43.Suche in Google Scholar

2. Moshetova, LK, Soshina, MM, Sychev, DA, Turkina, KI. Pharmacogenetics of timolol. Vestn Oftalmol 2019;3:137–43. https://doi.org/10.17116/oftalma2019135031137.Suche in Google Scholar PubMed

3. Avetisov, SE, Egorov, EA, Moshetova, LK, Neoroev, VV, Takhchidi, KP, editors. Ophthalmology: a national guide. Moscow: GEOTAR Media; 2013:716 p.Suche in Google Scholar

4. Moroi, SE, Raoof, DA, Reed, DM, Zollner, S, Qin, Z, Richards, JE. Progress toward personalized medicine for glaucoma. Expet Rev Ophthalmol 2009;4:145–61. https://doi.org/10.1586/eop.09.6.Suche in Google Scholar PubMed PubMed Central

5. Moshetova, LK, Soshina, MM, Sychev, DA, Turkina, KI. Practical pharmacogenetics for personalized management of glaucoma patients. Farmakogenetika i farmakogenomika. Pharmacogenet Genomics 2020:26–34. (In Russ). https://doi.org/10.37489/2588-0527-2020-1-26-34.Suche in Google Scholar

6. Egorov, EA, Egorov, AE. Beta-blockers in treatment of glaucoma. Back to the future. Literature review. RMJ Clinical Ophthalmology 2013;3:92.Suche in Google Scholar

7. Order of the ministry of health of the Russian federation of December 29, 2012 № 1700n “On approval of the standard of primary health care for glaucoma” [Online]. Available from: https://minzdrav.gov.ru/documents/8388-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-29-dekabrya-2012-g-1700n-ob-utverzhdenii-standarta-pervichnoy-mediko-sanitarnoy-pomoschi-pri-glaukome.Suche in Google Scholar

8. Medical Expenditure Panel Survey (MEPS) 2013-2019. Agency for Healthcare Research and Quality (AHRQ) ClinCalc DrugStats Database version 2021.10 [Online]. Available from: https://clincalc.com/DrugStats/Drugs/Timolol [Accessed 2022].Suche in Google Scholar

9. Egorov, EA, Astakhov, YS, Yerichev, VP, editors. National guideline on glaucoma for practicing physicians, 3rd ed. Moscow: GEOTAR-Media; 2015:12 p.Suche in Google Scholar

10. Grieshaber, MC. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance? An exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res 2010;29:79–93. https://doi.org/10.1016/j.preteyeres.2009.08.002.Suche in Google Scholar PubMed

11. Laverty, R. Catecholamines: role in health and disease. Drugs 1978;16:418–40. https://doi.org/10.2165/00003495-197816050-00003.Suche in Google Scholar PubMed

12. Leier, CV, Baker, ND, Weber, PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986;104:197–9. https://doi.org/10.7326/0003-4819-104-2-197.Suche in Google Scholar PubMed

13. Valvo, E, Gammaro, L, Tessitore, N, Fabris, A, Ortalda, V, Bedogna, V, et al.. Effects of timolol on blood pressure, systemic hemodynamics, plasma renin activity, and glomerular filtration rate in patients with essential hypertension. J Clin Pharmacol Ther Toxicol 1984;22:156–61.Suche in Google Scholar

14. Alvan, G, Calissendorf, B, Seideman, P, Wildmark, K, Wildmark, G. Absorbtion of ocular timolol. Clin Pharmocokinet 1980;5:95–100. https://doi.org/10.2165/00003088-198005010-00004.Suche in Google Scholar PubMed

15. Korte, JM, Kaila, T, Saari, KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002;240:430–5. https://doi.org/10.1007/s00417-002-0462-2.Suche in Google Scholar PubMed

16. Volotinen, M, Turpeinen, M, Tolonen, A, Uusitalo, J, Maenpaa, J, Pelkonen, O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos 2007;35:1135–41. https://doi.org/10.1124/dmd.106.012906.Suche in Google Scholar PubMed

17. Gaikovitch, EA, Cascorbi, I, Mrozikiewicz, PM, Brockmöller, J, Frötschl, R, Köpke, K, et al.. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303–12. https://doi.org/10.1007/s00228-003-0606-2.Suche in Google Scholar PubMed

18. Preskorn, SH, Kane, CP, Lobello, K, Nichols, AI, Fayyad, R, Buckley, G, et al.. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for Personalized Medicine. J Clin Psychiatr 2013;74:614–21. https://doi.org/10.4088/JCP.12m07807.Suche in Google Scholar PubMed

19. Petrović, J, Pešić, V, Lauschke, VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet 2020;1:88–94. https://doi.org/10.1038/s41431-019-0480-8.Suche in Google Scholar PubMed PubMed Central

20. Ikonnikova, AY, Filippova, MA, Surzhikov, SA, Pozhitnova, VO, Kazakov, RE, Lisitsa, TS, et al.. Biochip-based approach for comprehensive pharmacogenetic testing. Drug Metab Pers Ther 2020;36:33–40. https://doi.org/10.1515/dmpt-2020-0155.Suche in Google Scholar PubMed

21. Ju, S, Gao, Y, Cao, X, Zhang, XF, Yan, CC, Liu, FT. Association between the lower extremity deep venous thrombosis, the warfarin maintenance dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 genetic polymorphisms: a case-control study. Genet Test Mol Biomarkers 2017;21:539–46. https://doi.org/10.1089/gtmb.2017.0090.Suche in Google Scholar PubMed

22. Yang, Y, Wu, K, Yuan, H, Yu, M. Cytochrome oxidase 2D6 gene polymorphism in primary open — angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Therapeut 2009;25:163–71. https://doi.org/10.1089/jop.2008.0028.Suche in Google Scholar PubMed

23. Yuan, H, Yu, M, Yang, Y, Wu, K, Lin, X, Li, J. Association of CYP2D6 single — nucleotide polymorphism with response to ophthalmic timolol in primary open — angle glaucoma — a pilot study. J Ocul Pharmacol Therapeut 2010;26:497–501. https://doi.org/10.1089/jop.2010.0013.Suche in Google Scholar PubMed

24. Nieminen, T, Lehtimaki, T, Maenpaa, J, Ropo, A, Uusitalo, H, Kähönen, M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007;67:237–45. https://doi.org/10.1080/00365510601034736.Suche in Google Scholar PubMed

Received: 2022-03-08

Accepted: 2022-05-30

Published Online: 2022-08-24

Sie haben derzeit keinen Zugang zu diesem Inhalt.

Artikel in diesem Heft

https://doi.org/10.1515/dmpt-2022-0117

Schlagwörter für diesen Artikel

CYP2D6; glaucoma; ophthalmic timolol; pharmacogenetics; polymorphism